http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 17 Jul 2026 18:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Biohaven+Ltd.+++++++++++++For%3A+Jul+09++Filed+by%3A+Volles+Warren+Karl/26785361.html si-local-file:///var/storage/secattach/20260717/26785361.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Biohaven+Ltd.+++++++++++++For%3A+Jul+09++Filed+by%3A+Volles+Warren+Karl/26785361.html Fri, 17 Jul 2026 18:00:00 -0400 BHVN O.55910540 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Biohaven+Ltd.+++++++++++++For%3A+Jul+09++Filed+by%3A+Volles+Warren+Karl/26785361.html si-local-file:///var/storage/secattach/20260717/26785361.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Biohaven+Ltd.+++++++++++++For%3A+Jul+09++Filed+by%3A+Volles+Warren+Karl/26785361.html Fri, 17 Jul 2026 18:00:00 -0400 BHVN O.55910540 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Biohaven+Ltd.+++++++++++++For%3A+Jul+09/26753914.html si-local-file:///var/storage/secattach/20260709/26753914.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Biohaven+Ltd.+++++++++++++For%3A+Jul+09/26753914.html Thu, 09 Jul 2026 17:11:00 -0400 BHVN O.55910540 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Biohaven+Ltd.+++++++++++++For%3A+Jul+09/26753914.html si-local-file:///var/storage/secattach/20260709/26753914.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Biohaven+Ltd.+++++++++++++For%3A+Jul+09/26753914.html Thu, 09 Jul 2026 17:11:00 -0400 BHVN O.55910540 http://www.streetinsider.com/Corporate+News/Biohaven+names+new+discovery+head+as+CSO+shifts+to+part-time+role/26753851.html <p>Biohaven Ltd. (NYSE: BHVN) announced leadership changes in its scientific organization, effective July 13, 2026, according to a company statement.</p><p>David Pirman, Ph.D., has been promoted to Executive Vice President and Head of Discovery, where he will lead the company's internal drug-discovery organization and oversee research programs.</p><p>Bruce Car, the company's current Chief Scientific Officer, is retiring from that role and will transition to a newly created part-time position of Chief Innovation Officer. In that capacity, Dr. Car will focus on scientific initiatives and external collaborations, including work related to the company's partnership with Bexorg, Inc. Dr. Car will continue to serve http://www.streetinsider.com/Corporate+News/Biohaven+names+new+discovery+head+as+CSO+shifts+to+part-time+role/26753851.html Thu, 09 Jul 2026 17:01:15 -0400 BHVN http://www.streetinsider.com/Management+Changes/Biohaven+names+new+discovery+head+as+CSO+shifts+to+part-time+role/26753851.html <p>Biohaven Ltd. (NYSE: BHVN) announced leadership changes in its scientific organization, effective July 13, 2026, according to a company statement.</p><p>David Pirman, Ph.D., has been promoted to Executive Vice President and Head of Discovery, where he will lead the company's internal drug-discovery organization and oversee research programs.</p><p>Bruce Car, the company's current Chief Scientific Officer, is retiring from that role and will transition to a newly created part-time position of Chief Innovation Officer. In that capacity, Dr. Car will focus on scientific initiatives and external collaborations, including work related to the company's partnership with Bexorg, Inc. Dr. Car will continue to serve http://www.streetinsider.com/Management+Changes/Biohaven+names+new+discovery+head+as+CSO+shifts+to+part-time+role/26753851.html Thu, 09 Jul 2026 17:01:15 -0400 BHVN http://www.streetinsider.com/Hot+Corp.+News/Biohaven+names+new+discovery+head+as+CSO+shifts+to+part-time+role/26753851.html <p>Biohaven Ltd. (NYSE: BHVN) announced leadership changes in its scientific organization, effective July 13, 2026, according to a company statement.</p><p>David Pirman, Ph.D., has been promoted to Executive Vice President and Head of Discovery, where he will lead the company's internal drug-discovery organization and oversee research programs.</p><p>Bruce Car, the company's current Chief Scientific Officer, is retiring from that role and will transition to a newly created part-time position of Chief Innovation Officer. In that capacity, Dr. Car will focus on scientific initiatives and external collaborations, including work related to the company's partnership with Bexorg, Inc. Dr. Car will continue to serve http://www.streetinsider.com/Hot+Corp.+News/Biohaven+names+new+discovery+head+as+CSO+shifts+to+part-time+role/26753851.html Thu, 09 Jul 2026 17:01:15 -0400 BHVN http://www.streetinsider.com/Hot+Mgmt+Changes/Biohaven+names+new+discovery+head+as+CSO+shifts+to+part-time+role/26753851.html <p>Biohaven Ltd. (NYSE: BHVN) announced leadership changes in its scientific organization, effective July 13, 2026, according to a company statement.</p><p>David Pirman, Ph.D., has been promoted to Executive Vice President and Head of Discovery, where he will lead the company's internal drug-discovery organization and oversee research programs.</p><p>Bruce Car, the company's current Chief Scientific Officer, is retiring from that role and will transition to a newly created part-time position of Chief Innovation Officer. In that capacity, Dr. Car will focus on scientific initiatives and external collaborations, including work related to the company's partnership with Bexorg, Inc. Dr. Car will continue to serve http://www.streetinsider.com/Hot+Mgmt+Changes/Biohaven+names+new+discovery+head+as+CSO+shifts+to+part-time+role/26753851.html Thu, 09 Jul 2026 17:01:15 -0400 BHVN http://www.streetinsider.com/Press+Releases/Biohaven+Announces+Scientific+Leadership+Transitions/26753827.html <div class="xn-content"> <ul type="disc"><li><i><person>David Pirman</person>, Ph.D. promoted to Executive Vice President and Head of Discovery<br /><br /></i></li><li><i><person>Bruce Car</person>, Ph.D. transitioning from Chief Scientific Officer to new role as Chief Innovation Officer focusing on external collaborations<br /><br /></i></li><li><i><person>Warren Volles</person>, General Counsel and Chief Legal Officer, also designated an executive officer</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ct.newhvn" idsrc="xmltag.org" >NEW HAVEN, Conn.</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("<span value="NYSE:BHVN" idsrc="xmltag.org" >Biohaven</span>" or the "Company") today announced scientific leadership role transitions designed to accelerate drug innovation and external collaborations. <person>David Pirman</person>, Ph.D., has been promoted to Executive Vice President and Head of Discovery. In this http://www.streetinsider.com/Press+Releases/Biohaven+Announces+Scientific+Leadership+Transitions/26753827.html Thu, 09 Jul 2026 17:00:00 -0400 A.50216958 BHVN O.55910540 O.58020761 http://www.streetinsider.com/Press+Releases/Biohaven+Announces+Scientific+Leadership+Transitions/26753827.html <div class="xn-content"> <ul type="disc"><li><i><person>David Pirman</person>, Ph.D. promoted to Executive Vice President and Head of Discovery<br /><br /></i></li><li><i><person>Bruce Car</person>, Ph.D. transitioning from Chief Scientific Officer to new role as Chief Innovation Officer focusing on external collaborations<br /><br /></i></li><li><i><person>Warren Volles</person>, General Counsel and Chief Legal Officer, also designated an executive officer</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ct.newhvn" idsrc="xmltag.org" >NEW HAVEN, Conn.</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("<span value="NYSE:BHVN" idsrc="xmltag.org" >Biohaven</span>" or the "Company") today announced scientific leadership role transitions designed to accelerate drug innovation and external collaborations. <person>David Pirman</person>, Ph.D., has been promoted to Executive Vice President and Head of Discovery. In this http://www.streetinsider.com/Press+Releases/Biohaven+Announces+Scientific+Leadership+Transitions/26753827.html Thu, 09 Jul 2026 17:00:00 -0400 A.50216958 BHVN O.55910540 O.58020761 http://www.streetinsider.com/Press+Releases/Biohaven+Announces+Scientific+Leadership+Transitions/26753827.html <div class="xn-content"> <ul type="disc"><li><i><person>David Pirman</person>, Ph.D. promoted to Executive Vice President and Head of Discovery<br /><br /></i></li><li><i><person>Bruce Car</person>, Ph.D. transitioning from Chief Scientific Officer to new role as Chief Innovation Officer focusing on external collaborations<br /><br /></i></li><li><i><person>Warren Volles</person>, General Counsel and Chief Legal Officer, also designated an executive officer</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ct.newhvn" idsrc="xmltag.org" >NEW HAVEN, Conn.</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("<span value="NYSE:BHVN" idsrc="xmltag.org" >Biohaven</span>" or the "Company") today announced scientific leadership role transitions designed to accelerate drug innovation and external collaborations. <person>David Pirman</person>, Ph.D., has been promoted to Executive Vice President and Head of Discovery. In this http://www.streetinsider.com/Press+Releases/Biohaven+Announces+Scientific+Leadership+Transitions/26753827.html Thu, 09 Jul 2026 17:00:00 -0400 A.50216958 BHVN O.55910540 O.58020761 http://www.streetinsider.com/Press+Releases/Biohaven+Announces+Scientific+Leadership+Transitions/26753827.html <div class="xn-content"> <ul type="disc"><li><i><person>David Pirman</person>, Ph.D. promoted to Executive Vice President and Head of Discovery<br /><br /></i></li><li><i><person>Bruce Car</person>, Ph.D. transitioning from Chief Scientific Officer to new role as Chief Innovation Officer focusing on external collaborations<br /><br /></i></li><li><i><person>Warren Volles</person>, General Counsel and Chief Legal Officer, also designated an executive officer</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ct.newhvn" idsrc="xmltag.org" >NEW HAVEN, Conn.</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("<span value="NYSE:BHVN" idsrc="xmltag.org" >Biohaven</span>" or the "Company") today announced scientific leadership role transitions designed to accelerate drug innovation and external collaborations. <person>David Pirman</person>, Ph.D., has been promoted to Executive Vice President and Head of Discovery. In this http://www.streetinsider.com/Press+Releases/Biohaven+Announces+Scientific+Leadership+Transitions/26753827.html Thu, 09 Jul 2026 17:00:00 -0400 A.50216958 BHVN O.55910540 O.58020761 http://www.streetinsider.com/PRNewswire/Biohaven+Announces+Scientific+Leadership+Transitions/26753827.html <div class="xn-content"> <ul type="disc"><li><i><person>David Pirman</person>, Ph.D. promoted to Executive Vice President and Head of Discovery<br /><br /></i></li><li><i><person>Bruce Car</person>, Ph.D. transitioning from Chief Scientific Officer to new role as Chief Innovation Officer focusing on external collaborations<br /><br /></i></li><li><i><person>Warren Volles</person>, General Counsel and Chief Legal Officer, also designated an executive officer</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ct.newhvn" idsrc="xmltag.org" >NEW HAVEN, Conn.</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("<span value="NYSE:BHVN" idsrc="xmltag.org" >Biohaven</span>" or the "Company") today announced scientific leadership role transitions designed to accelerate drug innovation and external collaborations. <person>David Pirman</person>, Ph.D., has been promoted to Executive Vice President and Head of Discovery. In this http://www.streetinsider.com/PRNewswire/Biohaven+Announces+Scientific+Leadership+Transitions/26753827.html Thu, 09 Jul 2026 17:00:00 -0400 A.50216958 BHVN O.55910540 O.58020761 http://www.streetinsider.com/PRNewswire/Biohaven+Announces+Scientific+Leadership+Transitions/26753827.html <div class="xn-content"> <ul type="disc"><li><i><person>David Pirman</person>, Ph.D. promoted to Executive Vice President and Head of Discovery<br /><br /></i></li><li><i><person>Bruce Car</person>, Ph.D. transitioning from Chief Scientific Officer to new role as Chief Innovation Officer focusing on external collaborations<br /><br /></i></li><li><i><person>Warren Volles</person>, General Counsel and Chief Legal Officer, also designated an executive officer</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ct.newhvn" idsrc="xmltag.org" >NEW HAVEN, Conn.</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("<span value="NYSE:BHVN" idsrc="xmltag.org" >Biohaven</span>" or the "Company") today announced scientific leadership role transitions designed to accelerate drug innovation and external collaborations. <person>David Pirman</person>, Ph.D., has been promoted to Executive Vice President and Head of Discovery. In this http://www.streetinsider.com/PRNewswire/Biohaven+Announces+Scientific+Leadership+Transitions/26753827.html Thu, 09 Jul 2026 17:00:00 -0400 A.50216958 BHVN O.55910540 O.58020761 http://www.streetinsider.com/PRNewswire/Biohaven+Announces+Scientific+Leadership+Transitions/26753827.html <div class="xn-content"> <ul type="disc"><li><i><person>David Pirman</person>, Ph.D. promoted to Executive Vice President and Head of Discovery<br /><br /></i></li><li><i><person>Bruce Car</person>, Ph.D. transitioning from Chief Scientific Officer to new role as Chief Innovation Officer focusing on external collaborations<br /><br /></i></li><li><i><person>Warren Volles</person>, General Counsel and Chief Legal Officer, also designated an executive officer</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ct.newhvn" idsrc="xmltag.org" >NEW HAVEN, Conn.</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("<span value="NYSE:BHVN" idsrc="xmltag.org" >Biohaven</span>" or the "Company") today announced scientific leadership role transitions designed to accelerate drug innovation and external collaborations. <person>David Pirman</person>, Ph.D., has been promoted to Executive Vice President and Head of Discovery. In this http://www.streetinsider.com/PRNewswire/Biohaven+Announces+Scientific+Leadership+Transitions/26753827.html Thu, 09 Jul 2026 17:00:00 -0400 A.50216958 BHVN O.55910540 O.58020761 http://www.streetinsider.com/PRNewswire/Biohaven+Announces+Scientific+Leadership+Transitions/26753827.html <div class="xn-content"> <ul type="disc"><li><i><person>David Pirman</person>, Ph.D. promoted to Executive Vice President and Head of Discovery<br /><br /></i></li><li><i><person>Bruce Car</person>, Ph.D. transitioning from Chief Scientific Officer to new role as Chief Innovation Officer focusing on external collaborations<br /><br /></i></li><li><i><person>Warren Volles</person>, General Counsel and Chief Legal Officer, also designated an executive officer</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ct.newhvn" idsrc="xmltag.org" >NEW HAVEN, Conn.</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("<span value="NYSE:BHVN" idsrc="xmltag.org" >Biohaven</span>" or the "Company") today announced scientific leadership role transitions designed to accelerate drug innovation and external collaborations. <person>David Pirman</person>, Ph.D., has been promoted to Executive Vice President and Head of Discovery. In this http://www.streetinsider.com/PRNewswire/Biohaven+Announces+Scientific+Leadership+Transitions/26753827.html Thu, 09 Jul 2026 17:00:00 -0400 A.50216958 BHVN O.55910540 O.58020761 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Biohaven+Ltd.++++++++++++++++++++++++++Filed+by%3A+Janus+Henderson+Group+Ltd./26748491.html si-local-file:///var/storage/secattach/20260708/26748491.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Biohaven+Ltd.++++++++++++++++++++++++++Filed+by%3A+Janus+Henderson+Group+Ltd./26748491.html Wed, 08 Jul 2026 17:44:00 -0400 BHVN O.55910540 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Biohaven+Ltd.++++++++++++++++++++++++++Filed+by%3A+Janus+Henderson+Group+Ltd./26748491.html si-local-file:///var/storage/secattach/20260708/26748491.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Biohaven+Ltd.++++++++++++++++++++++++++Filed+by%3A+Janus+Henderson+Group+Ltd./26748491.html Wed, 08 Jul 2026 17:44:00 -0400 BHVN O.55910540 http://www.streetinsider.com/Corporate+News/Biohaven+completes+enrollment+in+focal+epilepsy+drug+trial/26709571.html <p>Biohaven Ltd. (NYSE: BHVN) announced the completion of enrollment in RISE3, a pivotal Phase 2/3 randomized, double-blind, placebo-controlled study evaluating opakalim, a selective Kv7.2/7.3 channel activator, for the treatment of refractory focal epilepsy. Top-line results are expected in the second half of 2026.</p><p>RISE3 (NCT06309966) enrolled adult participants with refractory focal onset seizures who experienced at least four seizures per month while taking one to three concurrent antiseizure medicines (ASMs). After an eight-week observation phase, participants were randomized to opakalim 75 mg, 50 mg, or placebo once daily as adjunctive therapy for an eight-week double-blind treatment period. The primary endpoint measures http://www.streetinsider.com/Corporate+News/Biohaven+completes+enrollment+in+focal+epilepsy+drug+trial/26709571.html Tue, 30 Jun 2026 07:31:33 -0400 BHVN http://www.streetinsider.com/FDA/Biohaven+completes+enrollment+in+focal+epilepsy+drug+trial/26709571.html <p>Biohaven Ltd. (NYSE: BHVN) announced the completion of enrollment in RISE3, a pivotal Phase 2/3 randomized, double-blind, placebo-controlled study evaluating opakalim, a selective Kv7.2/7.3 channel activator, for the treatment of refractory focal epilepsy. Top-line results are expected in the second half of 2026.</p><p>RISE3 (NCT06309966) enrolled adult participants with refractory focal onset seizures who experienced at least four seizures per month while taking one to three concurrent antiseizure medicines (ASMs). After an eight-week observation phase, participants were randomized to opakalim 75 mg, 50 mg, or placebo once daily as adjunctive therapy for an eight-week double-blind treatment period. The primary endpoint measures http://www.streetinsider.com/FDA/Biohaven+completes+enrollment+in+focal+epilepsy+drug+trial/26709571.html Tue, 30 Jun 2026 07:31:33 -0400 BHVN http://www.streetinsider.com/Press+Releases/Biohaven+Completes+Enrollment+in+RISE+3+Pivotal+Focal+Epilepsy+Study+with+Opakalim%2C+a+Selective+Kv7.27.3+Activator/26709532.html <div class="xn-content"> <ul type="disc"><li><i>Enrollment complete in pivotal Phase 2/3 study evaluating opakalim in focal epilepsy (RISE3); top-line results on track for 2H 2026</i></li><li><i>Emerging opakalim focal epilepsy and idiopathic generalized epilepsy data presented at recent R&amp;D Day reinforce evidence of target engagement, potential for efficacy, and differentiated tolerability profile</i><ul type="circle"><li><i>In the ongoing focal epilepsy open-label extension (OLE) study, 54% of participants on opakalim 75 mg once-daily achieved a ≥50% reduction in seizure frequency compared to pre-randomization baseline, with a markedly lower incidence of nervous system adverse events compared to approved and investigational ASMs </i></li><li><i>High double-blind completion rates of ~95%, and high rollover http://www.streetinsider.com/Press+Releases/Biohaven+Completes+Enrollment+in+RISE+3+Pivotal+Focal+Epilepsy+Study+with+Opakalim%2C+a+Selective+Kv7.27.3+Activator/26709532.html Tue, 30 Jun 2026 07:30:00 -0400 BHVN O.55910540 http://www.streetinsider.com/Press+Releases/Biohaven+Completes+Enrollment+in+RISE+3+Pivotal+Focal+Epilepsy+Study+with+Opakalim%2C+a+Selective+Kv7.27.3+Activator/26709532.html <div class="xn-content"> <ul type="disc"><li><i>Enrollment complete in pivotal Phase 2/3 study evaluating opakalim in focal epilepsy (RISE3); top-line results on track for 2H 2026</i></li><li><i>Emerging opakalim focal epilepsy and idiopathic generalized epilepsy data presented at recent R&amp;D Day reinforce evidence of target engagement, potential for efficacy, and differentiated tolerability profile</i><ul type="circle"><li><i>In the ongoing focal epilepsy open-label extension (OLE) study, 54% of participants on opakalim 75 mg once-daily achieved a ≥50% reduction in seizure frequency compared to pre-randomization baseline, with a markedly lower incidence of nervous system adverse events compared to approved and investigational ASMs </i></li><li><i>High double-blind completion rates of ~95%, and high rollover http://www.streetinsider.com/Press+Releases/Biohaven+Completes+Enrollment+in+RISE+3+Pivotal+Focal+Epilepsy+Study+with+Opakalim%2C+a+Selective+Kv7.27.3+Activator/26709532.html Tue, 30 Jun 2026 07:30:00 -0400 BHVN O.55910540 http://www.streetinsider.com/PRNewswire/Biohaven+Completes+Enrollment+in+RISE+3+Pivotal+Focal+Epilepsy+Study+with+Opakalim%2C+a+Selective+Kv7.27.3+Activator/26709532.html <div class="xn-content"> <ul type="disc"><li><i>Enrollment complete in pivotal Phase 2/3 study evaluating opakalim in focal epilepsy (RISE3); top-line results on track for 2H 2026</i></li><li><i>Emerging opakalim focal epilepsy and idiopathic generalized epilepsy data presented at recent R&amp;D Day reinforce evidence of target engagement, potential for efficacy, and differentiated tolerability profile</i><ul type="circle"><li><i>In the ongoing focal epilepsy open-label extension (OLE) study, 54% of participants on opakalim 75 mg once-daily achieved a ≥50% reduction in seizure frequency compared to pre-randomization baseline, with a markedly lower incidence of nervous system adverse events compared to approved and investigational ASMs </i></li><li><i>High double-blind completion rates of ~95%, and high rollover http://www.streetinsider.com/PRNewswire/Biohaven+Completes+Enrollment+in+RISE+3+Pivotal+Focal+Epilepsy+Study+with+Opakalim%2C+a+Selective+Kv7.27.3+Activator/26709532.html Tue, 30 Jun 2026 07:30:00 -0400 BHVN O.55910540 http://www.streetinsider.com/PRNewswire/Biohaven+Completes+Enrollment+in+RISE+3+Pivotal+Focal+Epilepsy+Study+with+Opakalim%2C+a+Selective+Kv7.27.3+Activator/26709532.html <div class="xn-content"> <ul type="disc"><li><i>Enrollment complete in pivotal Phase 2/3 study evaluating opakalim in focal epilepsy (RISE3); top-line results on track for 2H 2026</i></li><li><i>Emerging opakalim focal epilepsy and idiopathic generalized epilepsy data presented at recent R&amp;D Day reinforce evidence of target engagement, potential for efficacy, and differentiated tolerability profile</i><ul type="circle"><li><i>In the ongoing focal epilepsy open-label extension (OLE) study, 54% of participants on opakalim 75 mg once-daily achieved a ≥50% reduction in seizure frequency compared to pre-randomization baseline, with a markedly lower incidence of nervous system adverse events compared to approved and investigational ASMs </i></li><li><i>High double-blind completion rates of ~95%, and high rollover http://www.streetinsider.com/PRNewswire/Biohaven+Completes+Enrollment+in+RISE+3+Pivotal+Focal+Epilepsy+Study+with+Opakalim%2C+a+Selective+Kv7.27.3+Activator/26709532.html Tue, 30 Jun 2026 07:30:00 -0400 BHVN O.55910540 http://www.streetinsider.com/Options/Biohaven+Pharma+%28BHVN%29+call+put+ratio+7.5+calls+to+1+put+as+share+price+down+4.7%25/26706027.html <p>Biohaven Pharma (NYSE: BHVN) 30-day option implied volatility is at 97; compared to its 52-week range of 70 to 381. Call put ratio 7.5 calls to 1 put with a focus on July 12.5 and 15 calls as share price down 4.7%.</p> http://www.streetinsider.com/Options/Biohaven+Pharma+%28BHVN%29+call+put+ratio+7.5+calls+to+1+put+as+share+price+down+4.7%25/26706027.html Mon, 29 Jun 2026 15:27:21 -0400 BHVN